Loading data for CTOR — first visit, this takes a few seconds.

Оповещение

Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · Цена в реальном времени · USD

0.74

-0.18 (-19.57%)

На закрытии: Aug 19, 2026, 1:06 PM

-19.57% (1D)

Бид	0.54
Рыночная капитализация	79.33M
Выручка (TTM)	5.61M
Чистая прибыль (TTM)	-42.51M
Бета	3.49
EPS (TTM)	-0.48
P/E (TTM)	n/a
Прогнозный P/E	n/a
P/B (TTM)	1.98
P/S (TTM)	14.14
Earnings Date	n/a

Аск	0.98
Объём торгов	274,784
Ср. объём (20д)	80,365
Открытие	0.77
Пред. закрытие	0.92
Диапазон дня	0.70 - 0.78
Диапазон за 52 недели	0.49 - 2.25
Аналитики	n/a
Целевая цена	n/a
Дивиденды	n/a
Дата отсечки	n/a

О компании CTOR

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

[Читать далее]

Отрасль Drug Manufacturers - Specialty & Generic

Сектор Healthcare

Дата IPO Dec 8, 2022

Сотрудники n/a

Биржа NasdaqCM

Тикер CTOR

Сайт https://citiusonc.com/overview/default.aspx

Полный профиль компании

Финансовые результаты

В 2025 году выручка Citius Oncology составила 0 — это рост на undefined% к прошлогодним 0. Прибыль составила -24.76M — это рост на 17.08%.

Финансовая отчётность

Сюрприз в отчёте

Citius Oncology опубликовала квартальный отчёт Aug 14, 2026:

Выручка $1.67M ниже прогноза на $0, при Infinity% рост год к году.

EPS -0.08 ниже прогноза на -0.01, при 0.00% рост год к году.

Новости

2 дней назад · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

2 месяцев назад · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

3 месяцев назад · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4 месяцев назад · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

5 месяцев назад · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

Страница 1 из 2

Citius Oncology Inc. (CTOR)